Moody’s downgrades Senegal to Caa1 amid rising debt concerns
BURLINGTON, Mass. & NEW YORK - Butterfly Network, Inc. (NYSE:BFLY) has introduced an artificial intelligence-powered gestational age calculator in Malawi and Uganda, designed to improve maternal and fetal health outcomes in under-resourced areas.
The new tool, integrated directly into Butterfly’s app, allows healthcare workers to calculate gestational age through a simple blind-sweep scan without requiring image interpretation or specialized training. This innovation enables midwives and other healthcare providers to determine accurate gestational timing for critical interventions. The company’s strong cash position, highlighted as one of several key InvestingPro Tips, provides financial flexibility for continued innovation and global expansion.
Developed with support from the Gates Foundation and the University of North Carolina, the AI tool was specifically trained using data from African populations to ensure relevance and performance quality in the region.
"Our AI-powered gestational age tool is an accurate, fast and simple way for lower skilled healthcare workers in Sub-Saharan Africa to get expecting women the right care plans for the stage of their pregnancy journey," said Dr. Sachita Shah, Vice President of Global Health at Butterfly Network, according to a company press release.
The tool is currently pending FDA review for use in the United States.
Butterfly Network also reported progress from its 1,000 Probe Partnership, which has deployed handheld ultrasound probes and trained over 1,050 healthcare providers across South Africa and Kenya since September 2022. The company stated that 1.8 million scans have been conducted through July 2025, averaging 83,000 monthly.
Preliminary data from the initiative suggests positive impacts, with South African facilities reporting a 1.13% decrease in stillbirths and 20.6% decrease in maternal mortality in the Eastern Cape province during the 12 months following training implementation.
The company’s newest device, iQ3, has received approval for use in South Africa and Kenya. Butterfly Network develops handheld, whole-body ultrasound technology with its proprietary Ultrasound-on-Chip semiconductor technology. The stock has shown significant momentum with an 18.9% return over the past week, though InvestingPro data suggests the stock is currently trading above its Fair Value. Discover 8 additional exclusive ProTips and comprehensive financial analysis in the Pro Research Report, available to subscribers.
In other recent news, Butterfly Network reported record revenue of $23.4 million for the second quarter of 2025, reflecting a 9% increase compared to the previous year. The company’s earnings per share showed a loss of $0.03, which was better than analysts’ expectations of a $0.05 loss. Butterfly Network has adjusted its full-year revenue guidance to a range of $91 million to $95 million. In addition, TD Cowen reiterated its Buy rating for Butterfly Network, maintaining a price target of $3.50, following the positive results of the POCUS-CARE trial. This study highlighted the iQ3 device’s potential to reduce inpatient costs and length of stay, which strengthens the company’s clinical evidence base. Furthermore, Butterfly Network announced a partnership with Clipper Distributing to expand the availability of its iQ+ Vet ultrasound devices to veterinary practices across the United States. The company also appointed Victor Ku as the new Chief Technology Officer to lead its global technology strategy and product development. Ku brings extensive experience from previous roles at Headwall Photonics, Teledyne FLIR, and EFI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.